Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics reports developments in genomic medicine, with a pipeline centered on neurological diseases, Fabry disease gene therapy, zinc finger epigenetic regulation, capsid discovery and modular integrase technology. Company updates commonly cover clinical and nonclinical data presentations, regulatory submissions for isaralgagene civaparvovec, or ST-920, in Fabry disease, and neurology programs such as small fiber neuropathy and chronic neuropathic pain.
Recurring news also includes financial results, earnings calls, collaboration and licensing activity around neurotropic capsids, and public-company matters affecting SGMO common stock. Listing-status announcements, including Nasdaq compliance and OTCQB quotation matters, form part of the company's corporate-status coverage alongside pipeline and technology updates.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced its participation in two upcoming investor conferences. The Jefferies Virtual Gene Therapy / Editing Summit will take place on October 1st at 12:00 PM ET, followed by the Chardan Genetic Medicines Conference on October 5th at 8:00 AM ET. Both presentations will be webcast live and accessible via the Sangamo website's Investors and Media section. The company's focus is on developing genomic medicines, including gene therapy and genome editing.